gc1102
mAbexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Aug 1, 2012 (NCT01606163)
Timeline
Indications
Mechanism of action
- Hepatitis B virusImmunity, passive
Hepatitis B virus immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- gc1102
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03801798 | Phase 2 | Feb 11, 2019 | Green Cross Corporation, Yonsei University |
| NCT03519113 | Phase 2/Phase 3 (Phase 3) | Mar 29, 2018 | Green Cross Corporation, University of Ulsan |
| NCT02569372 | Phase 1 | Oct 1, 2015 | Green Cross Corporation, Yonsei University |
| NCT02304315 | Phase 2 | Feb 1, 2015 | Green Cross Corporation, University of Ulsan |
| NCT01606163 | Phase 1 | Aug 1, 2012 | Green Cross Corporation |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Green Cross Corporation | For profit | 5 | 5 | 3 | 2012 |
| University of Ulsan | Academic/Hospital | 2 | 0 | 2 | 2015 |
| Yonsei University | Academic/Hospital | 2 | 0 | 2 | 2015 |
3 organizations
Page 1 / 1